Form 4 for CRL Charles River Laboratories
Accepted 2022-06-01 00:00:00 ET · period of report 2022-05-27 · accession 0001127602-22-016211 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-01 | 2022-05-27 | CRL | Pease Flavia | CFO, Corp. Executive VP | A - Grant | $0.00 | +1,637 | 6,822 | +32% | $0 |
| D | 2022-06-01 | 2022-05-27 | CRL | Pease Flavia | CFO, Corp. Executive VP | A - Grant | $244.41 | +4,423 | 4,423 | New | +$1.08M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-27 | A | A | 1,637 | $0.00 | 6,822 | D | — | — | (F1) Unvested restricted stock units vest as follows: 409 on May 27, 2023, 409 on May 27, 2024, 409 on May 27, 2025 and 410 on May 27, 2026. |
| 2 | Derivative | Stock Options (Right to Buy) | 2022-05-27 | A | A | 4,423 | $244.41 | 4,423 | D | $244.41 · 2023-05-27 to 2032-05-27 | 4,423 Common Stock | (F2) Stock Options vest as follows: 1,105 on May 27, 2023, 1,106 on May 27, 2024, 1,106 on May 27, 2025 and 1,106 on May 27, 2026. |